{"gene":"LYVE1","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":1999,"finding":"LYVE-1 is a type I integral membrane glycoprotein with a single extracellular Link module that binds both soluble and immobilized hyaluronan (HA), functioning as the first characterized lymph-specific HA receptor on the luminal face of lymph vessel walls; it is 41% similar to CD44 but absent from blood vessels.","method":"Molecular cloning, recombinant protein HA-binding assays, immunolocalization (immunofluorescence and immunoelectron microscopy)","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 — original identification with multiple orthogonal methods (cloning, binding assay, localization), foundational paper with >1300 citations","pmids":["10037799"],"is_preprint":false},{"year":2001,"finding":"Mouse LYVE-1 acts as an endocytic receptor for hyaluronan: it both binds and internalizes HA in transfected 293T fibroblasts in vitro, and is distributed equally on luminal and abluminal surfaces of lymphatic vessels in vivo.","method":"Transfection of 293T fibroblasts with murine LYVE-1 cDNA, HA internalization assay, immunoelectron microscopy of lymphatic vessels, LYVE-1/CD44 double-knockout analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of endocytosis combined with in vivo immunoelectron microscopy and genetic control","pmids":["11278811"],"is_preprint":false},{"year":2007,"finding":"LYVE-1 surface expression is rapidly and reversibly lost from lymphatic endothelial cells after exposure to TNFα and TNFβ via internalization and lysosomal degradation, coupled with transcriptional shutdown; this internalization is largely HA-independent and occurs in vivo during allergen-induced skin inflammation.","method":"Primary lymphatic endothelial cell culture, cytokine treatment, flow cytometry, lysosomal inhibitor studies, ex vivo dermal explants, in vivo murine allergen model, adhesion-blocking mAb 3A","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in vitro and in vivo, rigorous controls, single lab","pmids":["17884820"],"is_preprint":false},{"year":2008,"finding":"LYVE-1 HA-binding activity is functionally silenced in lymphatic endothelial cells by cell-specific autoinhibitory terminal sialylation (via α2-3 or α2-6 linkage to O-glycans); neuraminidase treatment of the native ectodomain reactivates HA binding.","method":"Transfection into HEK 293T, Jurkat, CHO, and HeLa cells; mutagenesis of glycosylation sites; glycosylation-defective CHO cell lines; neuraminidase treatment; HA-binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with mutagenesis in multiple cell lines plus enzymatic reactivation, single rigorous study","pmids":["19033446"],"is_preprint":false},{"year":2009,"finding":"The LYVE-1 HA-binding domain uses six key residues (Tyr-87, Ile-97, Arg-99, Asn-103, Lys-105, Lys-108) forming a compact, predominantly electrostatic binding surface; unlike CD44, the extended Link module of LYVE-1 requires artificial dimerization for efficient HA binding, and a third conserved disulfide is critical for binding.","method":"Truncation mutagenesis, site-directed mutagenesis, recombinant soluble ectodomain production, HA-binding assays, bioluminescent resonance energy transfer (BRET) for dimerization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — structure-function mutagenesis with quantitative binding measurements, multiple orthogonal approaches","pmids":["19887450"],"is_preprint":false},{"year":2011,"finding":"LYVE-1 (identical to CRSBP-1) interacts with PDGF-BB and VEGF-A via their CRS motifs; CRSBP-1 ligands induce disruption of VE-cadherin-mediated intercellular adhesion in lymphatic endothelial cells through tyrosine phosphorylation of the CRSBP-1–PDGFβR–β-catenin complex, dissociation of β-catenin and p120-catenin from VE-cadherin, VE-cadherin internalization, and opening of intercellular junctions both in vitro and in vivo.","method":"Co-immunoprecipitation, immunofluorescence microscopy, Transwell permeability assay, PDGFβR kinase inhibitor treatment, FITC-dextran injection in wild-type and Crsbp1-null mice","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, in vitro signaling assays, and in vivo validation with knockout mouse","pmids":["21444752"],"is_preprint":false},{"year":2012,"finding":"FGF2 directly binds LYVE-1 with higher affinity than HA or PDGF-BB; glycosylation of LYVE-1 is required for FGF2 binding; soluble LYVE-1 and LYVE-1 knockdown impair FGF2 signaling and FGF2-induced lymphangiogenesis in vivo.","method":"AlphaScreen binding assay, surface-immobilization binding, solution-phase binding, CHO cell overexpression, siRNA knockdown in lymphatic endothelial cells, in vivo corneal lymphangiogenesis assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — multiple direct binding assays, functional knockdown, and in vivo confirmation","pmids":["23264596"],"is_preprint":false},{"year":2016,"finding":"HA binding by native LYVE-1 in lymphatic endothelium is critically dependent on avidity: receptor self-association above a critical density threshold and/or HA multimerization (via streptavidin or TSG-6 complexes) is required; surface clustering with divalent LYVE-1 mAbs activates binding; endogenous macrophage-surface HA engages LYVE-1 to facilitate macrophage adhesion and transit across lymphatic endothelium.","method":"Primary lymphatic endothelial cell HA-binding assays, divalent antibody cross-linking, biotinylated HA multimerization with streptavidin or TSG-6, macrophage adhesion assays on lymphatic endothelium","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal approaches in primary cells establishing avidity mechanism, single rigorous lab study","pmids":["26823460"],"is_preprint":false},{"year":2016,"finding":"LYVE-1 forms obligate disulfide-linked homodimers via an unpaired cysteine (Cys-201) in the membrane-proximal domain; homodimerization yields ~15-fold higher HA-binding affinity and ~67-fold slower off-rate than monomers; non-dimerizing mutants fail to bind HA even at high density or after antibody cross-linking; small-angle X-ray scattering (SAXS) indicates the homodimer adopts an 'open scissors' conformation; the Cys-201 disulfide is redox-labile, acting as a potential redox switch.","method":"Site-directed mutagenesis of Cys-201, disulfide-linked dimer detection by non-reducing SDS-PAGE, SAXS structural analysis, HA-binding affinity and kinetics measurements, TCEP-HCl reduction assay, lymphatic endothelial cell transfection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis + SAXS structural data + quantitative binding kinetics in a single rigorous study","pmids":["27733683"],"is_preprint":false},{"year":2016,"finding":"LYVE-1 ectodomain shedding is induced by VEGF-A via ERK and ADAM17 in lymphatic endothelial cells; wild-type but not uncleavable LYVE-1 promotes LEC migration in response to VEGF-A, implicating shedding in pathological lymphangiogenesis.","method":"Identification of cleavage site, generation of uncleavable LYVE-1 mutant, MEK inhibitor and ADAM17 inhibitor treatment, LEC migration assay, immunostaining in human psoriasis skin and VEGF-A transgenic mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — cleavage site mapping, uncleavable mutant functional rescue, in vitro and in vivo validation","pmids":["26966180"],"is_preprint":false},{"year":2017,"finding":"Dendritic cells dock to the basolateral surface of lymphatic vessels and transit to the lumen through HA-mediated interactions with LYVE-1, forming transmigratory cup-like structures; targeted deletion of Lyve1, antibody blockade, or depletion of the DC HA coat delayed lymphatic DC trafficking and blunted CD8+ T cell priming in skin-draining lymph nodes.","method":"Intravital microscopy, Lyve1 gene-targeted deletion, anti-LYVE-1 antibody blockade, hyaluronidase treatment of DC HA coat, DC adoptive transfer, in vivo T cell priming assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO, antibody blockade, and enzymatic depletion with defined cellular and immune phenotype, replicated across multiple approaches","pmids":["28504698"],"is_preprint":false},{"year":2018,"finding":"Arterial wall LYVE-1+ resident macrophages prevent arterial stiffness and collagen deposition by modulating collagen expression in smooth muscle cells via MMP-9-dependent proteolysis through engagement of LYVE-1 with the HA pericellular matrix of SMCs.","method":"Phenotyping and transcriptional profiling of aortic macrophages, targeted deletion of Csf1r, MMP-9 activity assays, co-culture of macrophages and SMCs, collagen quantification, arterial stiffness measurements","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic deletion, transcriptional profiling, enzymatic assay, and functional co-culture in a single study; >267 citations","pmids":["30054204"],"is_preprint":false},{"year":2020,"finding":"LYVE-1 lateral diffusion and HA-binding activity in primary lymphatic endothelial cells are regulated by the submembranous cortical actin network: actin disruption increases LYVE-1 diffusion and HA binding; LYVE-1 is transiently entrapped within actin corrals but unlike CD44 does not directly bind actin via cytoplasmic tail motifs.","method":"Super-resolution STED microscopy, fluorescence correlation spectroscopy, single-particle tracking, co-immunoprecipitation with actin, actin-disrupting drug treatments, HA-binding assays in primary LECs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple biophysical methods (STED, FCS, SPT) plus biochemical co-IP and functional binding assays in primary cells","pmids":["32034091"],"is_preprint":false},{"year":2014,"finding":"LMW-HA stimulation of lymphatic endothelial cells through LYVE-1 induces actin cytoskeleton rearrangement and rapid tyrosine phosphorylation of PKCα/βII and ERK1/2; neutralizing anti-LYVE-1 antibodies block these effects as well as LEC proliferation, migration, and tube formation.","method":"Primary LEC culture, anti-LYVE-1 neutralizing antibody, western blotting for phospho-PKC and phospho-ERK, actin immunofluorescence, proliferation and migration assays, tube formation assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — functional antibody blockade with signaling readouts, single lab, moderate evidence","pmids":["24667755"],"is_preprint":false},{"year":2015,"finding":"LMW-HA increases colocalization of LYVE-1 and S1P receptor S1P3 at the LEC surface; silencing either LYVE-1 or S1P3 inhibits LMW-HA-induced tube formation and blocks Src and ERK1/2 phosphorylation, indicating cooperative signaling between LYVE-1 and S1P3 in LMW-HA-mediated lymphangiogenesis.","method":"Immunofluorescence colocalization, co-immunoprecipitation, siRNA knockdown of LYVE-1 or S1P3, phospho-Src and phospho-ERK western blot, tube formation assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2–3 — co-IP and siRNA with functional readouts, single lab","pmids":["26116468"],"is_preprint":false},{"year":2006,"finding":"LYVE-1 knockout mice display normal lymphatic vessel ultrastructure and function, normal hyaluronan levels in tissue and blood, normal dendritic cell trafficking, normal skin inflammation resolution, and normal tumor growth, indicating LYVE-1 is not obligatory for these processes under normal conditions.","method":"Targeted gene replacement with beta-galactosidase reporter, immunoelectron microscopy, HA quantification in blood and tissue, DC trafficking assays, oxazolone inflammation model, tumor transplant models","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — comprehensive KO phenotyping with multiple functional assays; foundational loss-of-function study","pmids":["17101772"],"is_preprint":false},{"year":2009,"finding":"LYVE-1/CD44 double-knockout mice show increased edema formation in a carrageenan-induced paw inflammation model compared to wild-type, but not to single knockouts, suggesting LYVE-1 and CD44 have overlapping roles in inflammation, though neither is individually required for lymphatic formation or function.","method":"Generation of LYVE-1/CD44 double KO mice, histology, intravital microscopy, carrageenan-induced edema model","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis with double KO and functional edema readout, single lab","pmids":["19170073"],"is_preprint":false},{"year":2020,"finding":"FK506 (tacrolimus) downregulates LYVE-1 mRNA and protein in lymphatic endothelial cells through an NFAT-dependent transcriptional mechanism (identified via luciferase reporter assay with NFAT binding site on LYVE-1 promoter), resulting in decreased HA uptake; this effect was confirmed ex vivo in precision-cut lung slices.","method":"LEC culture, luciferase reporter assay with NFAT binding site mutagenesis, western blot, flow cytometry, HA uptake assay, ex vivo lung slice treatment","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase reporter with mutagenesis plus functional HA uptake assay, single lab","pmids":["32736525"],"is_preprint":false},{"year":2017,"finding":"Small HA (sHA) oligosaccharides promote LEC proliferation and lymphangiogenesis in a LYVE-1-dependent manner (using sialylated LYVE-1, not CD44 or TLR-4); higher sHA concentrations induce TGFβ in LECs to counter-regulate this proliferation; effects confirmed with LYVE-1 knockout mice and blocking antibodies.","method":"Primary LEC proliferation assays, ex vivo lymphangiogenesis assay, in vivo intradermal injection, LYVE-1 KO mice, blocking antibodies, TGFβ measurement","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO and antibody blockade with multiple functional assays, single lab","pmids":["29282520"],"is_preprint":false},{"year":2024,"finding":"OPN (osteopontin) acts as a ligand for LYVE-1 on tissue-resident macrophages (TRM-TAMs); OPN/LYVE-1 signaling activates the JNK/c-Jun pathway, promoting proliferation of immunosuppressive LYVE-1+ TRM-TAMs; IL-17A stimulates tumor cell CEBPβ to produce OPN; LYVE-1 deletion in macrophages inhibited TRM-TAM expansion and enhanced anti-tumor responses.","method":"In vitro signaling assays (JNK/c-Jun phosphorylation), macrophage-specific LYVE-1 conditional KO, OPN neutralization, IL-17A neutralization, tumor growth models, flow cytometry","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway placement, conditional KO with defined immune phenotype, single lab","pmids":["39643970"],"is_preprint":false},{"year":2025,"finding":"Crystal structures of murine and human LYVE-1 bound to hyaluronan reveal a highly unusual 'sliding' mode of ligand interaction (unlike the conventional 'sticking' mode of CD44): LYVE-1 grabs free HA chain-ends and winds them through conformational rearrangements in a deep binding cleft lubricated by structured waters, providing a low-tack adhesive interaction that allows migrating immune cells to slide through endothelial junctions while retaining their HA glycocalyx.","method":"X-ray crystallography of murine and human LYVE-1–HA complexes, surface plasmon resonance/binding mechanics, functional validation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structures of two species with mechanistic functional validation, rigorous single study","pmids":["40113779"],"is_preprint":false},{"year":2025,"finding":"Septal adipose tissue macrophages (sATMs) marked by LYVE-1 and CD209b reside in close proximity to adipocyte stem cells (ASCs) in the WAT septum; sATMs instruct ASC differentiation into white adipocytes through TGFβ1; depletion of sATMs or myeloid-specific loss of TGFβ1 redirects ASC fate toward thermogenic (beige) adipocytes and protects against diet-induced obesity.","method":"Genetic mouse model of LYVE-1+ macrophage depletion, TGFβ1 conditional KO in tissue-resident macrophages, adipocyte lineage tracing, co-culture of sATMs and ASCs, metabolic phenotyping","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — genetic depletion with conditional cytokine KO and co-culture functional rescue, rigorous mechanistic dissection","pmids":["40875853"],"is_preprint":false},{"year":2011,"finding":"LYVE-1 expressed on primary effusion lymphoma (PEL) cells interacts and colocalizes with emmprin (CD147) and BCRP/ABCG2 at the cell surface; RNA interference targeting of LYVE-1 enhances chemotherapy-induced apoptosis, and disruption of HA-receptor interactions with small HA oligosaccharides reduces emmprin and BCRP expression, sensitizing PEL cells to chemotherapy.","method":"Co-immunoprecipitation, immunofluorescence colocalization, siRNA knockdown of LYVE-1, apoptosis assay, small HA oligosaccharide treatment","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2–3 — reciprocal co-IP with siRNA functional validation, single lab","pmids":["21660043"],"is_preprint":false}],"current_model":"LYVE-1 is a type I transmembrane Link superfamily glycoprotein that forms obligate redox-labile disulfide homodimers (via Cys-201) and binds hyaluronan through a sliding, avidity-dependent mechanism requiring receptor clustering above a critical density threshold, a process constrained by the cortical actin network; in lymphatic endothelium it is functionally silenced by terminal sialylation of O-glycans and can be activated by cytokine-induced internalization or ligand multimerization, enabling it to serve as a docking receptor for dendritic cell and macrophage HA glycocalyx to mediate lymphatic entry and immune trafficking, to interact with FGF2 and growth factor co-receptors to regulate lymphangiogenesis, to activate intracellular signaling (PKC, ERK, JNK) downstream of low-MW HA, and to mediate MMP-9-dependent regulation of smooth muscle cell collagen by perivascular macrophages; its transcription is regulated by NFAT, and its ectodomain can be shed by ADAM17 downstream of VEGF-A/ERK signaling to promote LEC migration."},"narrative":{"teleology":[{"year":1999,"claim":"The identification of LYVE-1 as a lymph vessel-specific HA receptor established the first molecular distinction between lymphatic and blood vascular endothelium and opened the question of how HA transport and signaling occur in lymphatics.","evidence":"Molecular cloning, recombinant HA-binding assays, and immunolocalization by immunofluorescence and immunoelectron microscopy","pmids":["10037799"],"confidence":"High","gaps":["No structural information on the HA-binding mode","Functional role in vivo unknown","Signaling capacity not addressed"]},{"year":2001,"claim":"Demonstration that LYVE-1 acts as an endocytic receptor for HA, distributed on both luminal and abluminal lymphatic surfaces, established it as an active HA uptake mediator rather than merely a passive adhesion molecule.","evidence":"Transfection of 293T cells with murine LYVE-1, HA internalization assays, immunoelectron microscopy of lymphatic vessels","pmids":["11278811"],"confidence":"High","gaps":["Endocytic pathway and sorting signals not defined","Physiological relevance of HA uptake not tested in vivo"]},{"year":2006,"claim":"A comprehensive LYVE-1 knockout revealed unexpectedly normal lymphatic morphology, HA homeostasis, and DC trafficking under baseline conditions, raising the question of functional redundancy versus context-dependent activation.","evidence":"Targeted gene replacement in mice with multiple functional assays including HA quantification, DC trafficking, and tumor models","pmids":["17101772"],"confidence":"High","gaps":["Compensatory mechanisms (e.g., CD44) not fully dissected","Inflammatory or stress-dependent phenotypes not comprehensively explored"]},{"year":2007,"claim":"The finding that TNFα/β drive rapid internalization and degradation of LYVE-1 in inflamed lymphatics showed that receptor surface availability is dynamically regulated by inflammatory cytokines, explaining context-dependent function.","evidence":"Primary LEC culture with cytokine treatment, flow cytometry, lysosomal inhibitors, in vivo murine allergen model","pmids":["17884820"],"confidence":"High","gaps":["Trafficking route and sorting signals for internalization undefined","Whether internalization serves a signaling versus clearance function unknown"]},{"year":2008,"claim":"Discovery that autoinhibitory sialylation of O-glycans silences LYVE-1 HA binding on LECs, reversible by neuraminidase, revealed a glycan-based gating mechanism that explains why the receptor is not constitutively active despite high surface expression.","evidence":"Transfection into multiple cell lines, glycosylation site mutagenesis, glycosylation-defective cell lines, neuraminidase treatment and HA-binding assays","pmids":["19033446"],"confidence":"High","gaps":["Identity of the sialyltransferase(s) responsible not determined","Physiological signals that trigger desialylation in vivo unknown"]},{"year":2009,"claim":"Mapping the HA-binding surface to six key residues and showing that dimerization is required for efficient binding established the structural basis for LYVE-1's low intrinsic affinity and its dependence on avidity, distinguishing it mechanistically from CD44.","evidence":"Site-directed and truncation mutagenesis, recombinant ectodomain binding assays, BRET dimerization measurements","pmids":["19887450"],"confidence":"High","gaps":["No atomic-resolution structure yet available","How dimerization is regulated in vivo unresolved"]},{"year":2009,"claim":"LYVE-1/CD44 double-knockout mice showed enhanced inflammatory edema compared to single knockouts, providing genetic evidence for overlapping HA receptor functions in inflammation and partially explaining the mild single-KO phenotype.","evidence":"Double-KO mice, carrageenan-induced paw edema model, intravital microscopy","pmids":["19170073"],"confidence":"Medium","gaps":["Other compensating HA receptors not excluded","Mechanism of edema regulation not molecularly defined"]},{"year":2011,"claim":"Identification of LYVE-1 (as CRSBP-1) as a co-receptor for PDGF-BB and VEGF-A that disrupts VE-cadherin junctions via PDGFβR/β-catenin phosphorylation expanded the receptor's role from HA binding to growth factor signaling and junctional permeability regulation.","evidence":"Co-immunoprecipitation, Transwell permeability assay, kinase inhibitors, FITC-dextran injection in WT and Crsbp1-null mice","pmids":["21444752"],"confidence":"High","gaps":["Stoichiometry and direct binding interface between LYVE-1 and PDGFβR not resolved","Whether this pathway operates in all lymphatic beds unclear"]},{"year":2012,"claim":"Demonstration of direct FGF2 binding to LYVE-1 with higher affinity than HA, and its requirement for FGF2-induced lymphangiogenesis, established LYVE-1 as a multi-ligand co-receptor for angiogenic growth factors beyond the HA axis.","evidence":"AlphaScreen and surface-immobilization binding assays, siRNA knockdown, in vivo corneal lymphangiogenesis","pmids":["23264596"],"confidence":"High","gaps":["FGF2 binding site on LYVE-1 not structurally mapped","Relationship between FGF2 and HA binding (competitive or cooperative) not defined"]},{"year":2014,"claim":"LMW-HA-induced activation of PKCα/βII and ERK1/2 signaling through LYVE-1 in LECs, blocked by neutralizing antibodies, placed LYVE-1 upstream of intracellular kinase cascades that drive lymphangiogenic cell behaviors.","evidence":"Primary LEC culture, anti-LYVE-1 antibody blockade, western blotting for phospho-PKC and phospho-ERK, tube formation and migration assays","pmids":["24667755"],"confidence":"Medium","gaps":["Direct signaling adapter linking LYVE-1 cytoplasmic tail to PKC/ERK not identified","Single-lab finding without independent replication"]},{"year":2015,"claim":"Cooperative signaling between LYVE-1 and S1P3 in LMW-HA-mediated lymphangiogenesis, via Src and ERK1/2, revealed LYVE-1 participates in receptor crosstalk beyond its own cytoplasmic signaling capacity.","evidence":"Co-immunoprecipitation, siRNA knockdown of LYVE-1 or S1P3, phospho-Src and phospho-ERK western blot, tube formation assay","pmids":["26116468"],"confidence":"Medium","gaps":["Whether LYVE-1–S1P3 interaction is direct or scaffold-mediated not determined","Single-lab finding"]},{"year":2016,"claim":"Three concurrent studies resolved the biophysical mechanism of LYVE-1 HA binding: obligate Cys-201 disulfide homodimerization provides a redox-labile switch controlling affinity; avidity-dependent clustering above a threshold density is required for binding on native LECs; and VEGF-A/ERK-driven ADAM17 shedding of the ectodomain promotes LEC migration.","evidence":"Mutagenesis of Cys-201 with SAXS structural analysis and binding kinetics; divalent antibody cross-linking and HA multimerization assays; cleavage site mapping with uncleavable mutant and ADAM17 inhibitor studies","pmids":["27733683","26823460","26966180"],"confidence":"High","gaps":["Physiological redox signals controlling the Cys-201 switch unidentified","Signals that cluster LYVE-1 above the threshold in vivo unknown","Fate and function of shed ectodomain in vivo not defined"]},{"year":2017,"claim":"In vivo demonstration that DCs dock to LYVE-1 via their HA glycocalyx and form transmigratory cups for lymphatic entry, with LYVE-1 deletion delaying DC trafficking and blunting CD8+ T cell priming, established the first non-redundant immune function for LYVE-1 that the earlier KO had missed.","evidence":"Intravital microscopy, Lyve1 gene-targeted deletion, antibody blockade, hyaluronidase treatment of DC HA coat, adoptive DC transfer, T cell priming assays","pmids":["28504698"],"confidence":"High","gaps":["Whether all DC subsets use this pathway equally unclear","Structural basis of transmigratory cup formation not resolved"]},{"year":2018,"claim":"LYVE-1+ perivascular macrophages were shown to prevent arterial stiffness by engaging smooth muscle cell HA and inducing MMP-9-dependent collagen regulation, extending LYVE-1 function from lymphatic biology to vascular homeostasis.","evidence":"Aortic macrophage profiling, Csf1r deletion, MMP-9 activity assays, macrophage–SMC co-culture, arterial stiffness measurements","pmids":["30054204"],"confidence":"High","gaps":["Whether LYVE-1 engagement directly triggers MMP-9 secretion or acts indirectly not resolved","Relevance to human arterial disease not established"]},{"year":2020,"claim":"Super-resolution imaging revealed that cortical actin corrals regulate LYVE-1 lateral diffusion and clustering, constraining HA-binding capacity independently of direct cytoplasmic tail–actin interactions, adding a cytoskeletal layer to the avidity-gating model.","evidence":"STED microscopy, fluorescence correlation spectroscopy, single-particle tracking, co-IP with actin, actin-disrupting drugs in primary LECs","pmids":["32034091"],"confidence":"High","gaps":["Identity of linker proteins mediating indirect actin coupling unknown","How cytokine signals remodel actin corrals to activate LYVE-1 not defined"]},{"year":2020,"claim":"NFAT-dependent transcription of LYVE-1 was demonstrated, with FK506 suppressing LYVE-1 expression and HA uptake, linking calcineurin/NFAT signaling to lymphatic HA clearance.","evidence":"Luciferase reporter with NFAT-site mutagenesis, western blot, flow cytometry, HA uptake assay, ex vivo lung slices","pmids":["32736525"],"confidence":"Medium","gaps":["Which NFAT family member is responsible not specified","In vivo significance for transplant-associated lymphatic dysfunction not tested"]},{"year":2024,"claim":"Osteopontin was identified as a non-HA ligand for LYVE-1 on tumor-associated macrophages, activating JNK/c-Jun to expand immunosuppressive LYVE-1+ macrophages, linking LYVE-1 to tumor immune evasion beyond its classical HA-binding role.","evidence":"In vitro JNK/c-Jun signaling assays, macrophage-specific LYVE-1 conditional KO, OPN neutralization, tumor growth models","pmids":["39643970"],"confidence":"Medium","gaps":["OPN binding site on LYVE-1 not mapped","Whether OPN competes with HA for LYVE-1 binding unknown","Single-lab finding requiring independent validation"]},{"year":2025,"claim":"Crystal structures of LYVE-1–HA complexes from two species revealed a unique 'sliding' binding mode in which LYVE-1 grabs free HA chain-ends and winds them through a deep, water-lubricated cleft, explaining how immune cells retain their HA glycocalyx while sliding through lymphatic junctions—resolving the long-standing puzzle of low-tack adhesion.","evidence":"X-ray crystallography of murine and human LYVE-1–HA complexes, surface plasmon resonance, functional validation","pmids":["40113779"],"confidence":"High","gaps":["Whether the sliding mechanism applies equally to all HA polymer sizes not tested","How sialylation inhibits binding at the structural level not shown in these structures"]},{"year":2025,"claim":"LYVE-1+ septal adipose tissue macrophages were found to instruct white adipocyte differentiation via TGFβ1, with their depletion redirecting adipocyte progenitors toward thermogenic beige fate and protecting against obesity, revealing a metabolic regulatory role for LYVE-1+ macrophages.","evidence":"Genetic depletion of LYVE-1+ macrophages, myeloid-specific TGFβ1 conditional KO, adipocyte lineage tracing, metabolic phenotyping","pmids":["40875853"],"confidence":"High","gaps":["Whether LYVE-1 itself transduces signals in sATMs or serves only as a marker not distinguished","Relevance to human obesity not established"]},{"year":null,"claim":"Key unresolved questions include: the physiological signals that desialylate or cluster LYVE-1 above its activation threshold in vivo, the identity of cytoplasmic signaling adaptors, whether the sliding binding mode generalizes across all polymer contexts, and whether LYVE-1's roles on tissue-resident macrophages reflect receptor-mediated signaling or merely mark a macrophage subset.","evidence":"","pmids":[],"confidence":"Low","gaps":["Physiological desialylation trigger unknown","No cytoplasmic adaptor or signaling scaffold identified","Functional distinction between LYVE-1 as receptor vs. macrophage subset marker not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0,1,7,8,20]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,6,11]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,7,8,12]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,11,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,13,14]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[11]}],"complexes":[],"partners":["FGF2","PDGFB","VEGFA","PDGFRB","S1PR3","SPP1","BSG","ADAM17"],"other_free_text":[]},"mechanistic_narrative":"LYVE-1 is a lymphatic endothelial hyaluronan receptor of the Link superfamily that serves as a docking platform for immune cell trafficking across lymphatic vessels and as a co-receptor for growth factor signaling during lymphangiogenesis. It forms obligate disulfide-linked homodimers via Cys-201, adopting an open-scissors conformation that binds hyaluronan through a unique sliding mechanism—grabbing free HA chain-ends into a deep cleft—with ~15-fold higher affinity than monomers, and its HA-binding activity is regulated by avidity-dependent receptor clustering, autoinhibitory sialylation of O-glycans, cortical actin corralling, and redox-sensitive disulfide switching [PMID:27733683, PMID:40113779, PMID:19033446, PMID:26823460, PMID:32034091]. Dendritic cells and macrophages dock to LYVE-1 via their HA glycocalyx to transit lymphatic endothelium, forming transmigratory cups that facilitate immune cell entry and CD8+ T cell priming; on perivascular macrophages, LYVE-1 engagement with smooth muscle cell HA drives MMP-9-dependent collagen regulation to maintain arterial compliance [PMID:28504698, PMID:30054204]. LYVE-1 also directly binds FGF2, PDGF-BB, VEGF-A, and osteopontin, coupling to intracellular signaling cascades including PKC/ERK, Src, and JNK/c-Jun, while its ectodomain is shed by ADAM17 downstream of VEGF-A/ERK to promote lymphatic endothelial cell migration [PMID:23264596, PMID:21444752, PMID:39643970, PMID:26966180]."},"prefetch_data":{"uniprot":{"accession":"Q9Y5Y7","full_name":"Lymphatic vessel endothelial hyaluronic acid receptor 1","aliases":["Cell surface retention sequence-binding protein 1","CRSBP-1","Extracellular link domain-containing protein 1","Hyaluronic acid receptor"],"length_aa":322,"mass_kda":35.2,"function":"Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes (PubMed:10037799). Binds to pericelluar hyaluronan matrices deposited on the surface of leukocytes and facilitates cell adhesion and migration through lymphatic endothelium (PubMed:26823460)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9Y5Y7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LYVE1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LYVE1","total_profiled":1310},"omim":[{"mim_id":"620014","title":"LYMPHATIC MALFORMATION 12; LMPHM12","url":"https://www.omim.org/entry/620014"},{"mim_id":"616065","title":"PILR-ALPHA-ASSOCIATED NEURAL PROTEIN; PIANP","url":"https://www.omim.org/entry/616065"},{"mim_id":"605702","title":"LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; LYVE1","url":"https://www.omim.org/entry/605702"},{"mim_id":"300091","title":"FOS-INDUCED GROWTH FACTOR; FIGF","url":"https://www.omim.org/entry/300091"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":118.2},{"tissue":"placenta","ntpm":140.3}],"url":"https://www.proteinatlas.org/search/LYVE1"},"hgnc":{"alias_symbol":["LYVE-1"],"prev_symbol":["XLKD1"]},"alphafold":{"accession":"Q9Y5Y7","domains":[{"cath_id":"3.10.100.10","chopping":"27-132","consensus_level":"medium","plddt":95.8623,"start":27,"end":132}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5Y7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5Y7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y5Y7-F1-predicted_aligned_error_v6.png","plddt_mean":68.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LYVE1","jax_strain_url":"https://www.jax.org/strain/search?query=LYVE1"},"sequence":{"accession":"Q9Y5Y7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y5Y7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y5Y7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y5Y7"}},"corpus_meta":[{"pmid":"10037799","id":"PMC_10037799","title":"LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10037799","citation_count":1308,"is_preprint":false},{"pmid":"11278811","id":"PMC_11278811","title":"Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278811","citation_count":395,"is_preprint":false},{"pmid":"11719431","id":"PMC_11719431","title":"LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11719431","citation_count":350,"is_preprint":false},{"pmid":"11377291","id":"PMC_11377291","title":"LYVE-1, the lymphatic system and tumor lymphangiogenesis.","date":"2001","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11377291","citation_count":284,"is_preprint":false},{"pmid":"30054204","id":"PMC_30054204","title":"Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30054204","citation_count":267,"is_preprint":false},{"pmid":"17272806","id":"PMC_17272806","title":"Angiogenic role of LYVE-1-positive macrophages in adipose tissue.","date":"2007","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/17272806","citation_count":240,"is_preprint":false},{"pmid":"16482496","id":"PMC_16482496","title":"Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis.","date":"2006","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16482496","citation_count":228,"is_preprint":false},{"pmid":"12091407","id":"PMC_12091407","title":"Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin.","date":"2002","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12091407","citation_count":198,"is_preprint":false},{"pmid":"15705793","id":"PMC_15705793","title":"Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15705793","citation_count":197,"is_preprint":false},{"pmid":"15563314","id":"PMC_15563314","title":"Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis.","date":"2004","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/15563314","citation_count":177,"is_preprint":false},{"pmid":"22627281","id":"PMC_22627281","title":"lyve1 expression reveals novel lymphatic vessels and new mechanisms for lymphatic vessel development in zebrafish.","date":"2012","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22627281","citation_count":172,"is_preprint":false},{"pmid":"12554094","id":"PMC_12554094","title":"The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1.","date":"2003","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12554094","citation_count":171,"is_preprint":false},{"pmid":"17101772","id":"PMC_17101772","title":"Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17101772","citation_count":166,"is_preprint":false},{"pmid":"15534085","id":"PMC_15534085","title":"High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15534085","citation_count":150,"is_preprint":false},{"pmid":"28504698","id":"PMC_28504698","title":"Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1.","date":"2017","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28504698","citation_count":150,"is_preprint":false},{"pmid":"17884820","id":"PMC_17884820","title":"Inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17884820","citation_count":122,"is_preprint":false},{"pmid":"29425695","id":"PMC_29425695","title":"Hyaluronan in the lymphatics: The key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking.","date":"2018","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29425695","citation_count":116,"is_preprint":false},{"pmid":"17460275","id":"PMC_17460275","title":"LYVE-1-positive macrophages are present in normal murine eyes.","date":"2007","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/17460275","citation_count":105,"is_preprint":false},{"pmid":"18570254","id":"PMC_18570254","title":"Expression of the hyaluronan receptor LYVE-1 is not restricted to the lymphatic vasculature; LYVE-1 is also expressed on embryonic blood vessels.","date":"2008","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/18570254","citation_count":104,"is_preprint":false},{"pmid":"26823460","id":"PMC_26823460","title":"Binding of Hyaluronan to the Native Lymphatic Vessel Endothelial Receptor LYVE-1 Is Critically Dependent on Receptor Clustering and Hyaluronan Organization.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26823460","citation_count":96,"is_preprint":false},{"pmid":"18689706","id":"PMC_18689706","title":"The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive macrophages.","date":"2008","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/18689706","citation_count":87,"is_preprint":false},{"pmid":"24667755","id":"PMC_24667755","title":"Low molecular weight hyaluronan induces lymphangiogenesis through LYVE-1-mediated signaling pathways.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24667755","citation_count":82,"is_preprint":false},{"pmid":"27880904","id":"PMC_27880904","title":"LYVE1 Marks the Divergence of Yolk Sac Definitive Hemogenic Endothelium from the Primitive Erythroid Lineage.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27880904","citation_count":63,"is_preprint":false},{"pmid":"23264596","id":"PMC_23264596","title":"Evidence for the interaction of fibroblast growth factor-2 with the lymphatic endothelial cell marker LYVE-1.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23264596","citation_count":62,"is_preprint":false},{"pmid":"36450771","id":"PMC_36450771","title":"Deciphering the heterogeneity of the Lyve1+ perivascular macrophages in the mouse brain.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36450771","citation_count":59,"is_preprint":false},{"pmid":"18078989","id":"PMC_18078989","title":"DC-sign+ CD163+ macrophages expressing hyaluronan receptor LYVE-1 are located within chorion villi of the placenta.","date":"2008","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/18078989","citation_count":59,"is_preprint":false},{"pmid":"23836558","id":"PMC_23836558","title":"Conditional ablation of LYVE-1+ cells unveils defensive roles of lymphatic vessels in intestine and lymph nodes.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23836558","citation_count":59,"is_preprint":false},{"pmid":"30655286","id":"PMC_30655286","title":"Long noncoding RNA ANRIL regulates endothelial cell activities associated with coronary artery disease by up-regulating CLIP1, EZR, and LYVE1 genes.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30655286","citation_count":58,"is_preprint":false},{"pmid":"15201747","id":"PMC_15201747","title":"Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1).","date":"2004","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/15201747","citation_count":58,"is_preprint":false},{"pmid":"21660043","id":"PMC_21660043","title":"Cooperative roles for emmprin and LYVE-1 in the regulation of chemoresistance for primary effusion lymphoma.","date":"2011","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/21660043","citation_count":53,"is_preprint":false},{"pmid":"16303945","id":"PMC_16303945","title":"Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells.","date":"2005","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/16303945","citation_count":52,"is_preprint":false},{"pmid":"34714329","id":"PMC_34714329","title":"LYVE1+ macrophages of murine peritoneal mesothelium promote omentum-independent ovarian tumor growth.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34714329","citation_count":51,"is_preprint":false},{"pmid":"19033446","id":"PMC_19033446","title":"A mechanism of sialylation functionally silences the hyaluronan receptor LYVE-1 in lymphatic endothelium.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19033446","citation_count":51,"is_preprint":false},{"pmid":"14722766","id":"PMC_14722766","title":"Immunohistochemical detection of human small lymphatic vessels under normal and pathological conditions using the LYVE-1 antibody.","date":"2004","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14722766","citation_count":51,"is_preprint":false},{"pmid":"21181199","id":"PMC_21181199","title":"Expression of lymphatic endothelium-specific hyaluronan receptor LYVE-1 in the developing mouse kidney.","date":"2010","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/21181199","citation_count":48,"is_preprint":false},{"pmid":"19887450","id":"PMC_19887450","title":"Distinctive properties of the hyaluronan-binding domain in the lymphatic endothelial receptor Lyve-1 and their implications for receptor function.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19887450","citation_count":47,"is_preprint":false},{"pmid":"15976338","id":"PMC_15976338","title":"The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status.","date":"2005","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15976338","citation_count":46,"is_preprint":false},{"pmid":"19908110","id":"PMC_19908110","title":"Expression of LYVE-1 in sinusoidal endothelium is reduced in chronically inflamed human livers.","date":"2009","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19908110","citation_count":44,"is_preprint":false},{"pmid":"18599080","id":"PMC_18599080","title":"Fluorescent LYVE-1 antibody to image dynamically lymphatic trafficking of cancer cells in vivo.","date":"2008","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/18599080","citation_count":44,"is_preprint":false},{"pmid":"37442140","id":"PMC_37442140","title":"LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer.","date":"2023","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/37442140","citation_count":40,"is_preprint":false},{"pmid":"33945869","id":"PMC_33945869","title":"Nectin-4 promotes lymphangiogenesis and lymphatic metastasis in breast cancer by regulating CXCR4-LYVE-1 axis.","date":"2021","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33945869","citation_count":39,"is_preprint":false},{"pmid":"19170073","id":"PMC_19170073","title":"Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19170073","citation_count":35,"is_preprint":false},{"pmid":"16569201","id":"PMC_16569201","title":"Expression of lymphatic vascular endothelial hyaluronan receptor-1 (LYVE-1) in the human placenta.","date":"2006","source":"Lymphatic research and biology","url":"https://pubmed.ncbi.nlm.nih.gov/16569201","citation_count":34,"is_preprint":false},{"pmid":"21444752","id":"PMC_21444752","title":"CRSBP-1/LYVE-1 ligands disrupt lymphatic intercellular adhesion by inducing tyrosine phosphorylation and internalization of VE-cadherin.","date":"2011","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/21444752","citation_count":34,"is_preprint":false},{"pmid":"26966180","id":"PMC_26966180","title":"Ectodomain Shedding of Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE-1) Is Induced by Vascular Endothelial Growth Factor A (VEGF-A).","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26966180","citation_count":34,"is_preprint":false},{"pmid":"16251871","id":"PMC_16251871","title":"A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity.","date":"2005","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16251871","citation_count":33,"is_preprint":false},{"pmid":"26116468","id":"PMC_26116468","title":"The cooperative role of S1P3 with LYVE-1 in LMW-HA-induced lymphangiogenesis.","date":"2015","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26116468","citation_count":31,"is_preprint":false},{"pmid":"20011036","id":"PMC_20011036","title":"Lymphatic vascularisation and involvement of Lyve-1+ macrophages in the human onchocerca nodule.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20011036","citation_count":31,"is_preprint":false},{"pmid":"24436193","id":"PMC_24436193","title":"Enrichment of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)-positive macrophages around blood vessels in the normal human sclera.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24436193","citation_count":31,"is_preprint":false},{"pmid":"35338195","id":"PMC_35338195","title":"Kinetics of LYVE-1-positive M2-like macrophages in developing and repairing dental pulp in vivo and their pro-angiogenic activity in vitro.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35338195","citation_count":30,"is_preprint":false},{"pmid":"16353487","id":"PMC_16353487","title":"LYVE-1 expression on high endothelial venules (HEVs) of lymph nodes.","date":"2005","source":"Lymphology","url":"https://pubmed.ncbi.nlm.nih.gov/16353487","citation_count":30,"is_preprint":false},{"pmid":"17145628","id":"PMC_17145628","title":"Significance of lymphatic invasion on regional lymph node metastasis in early gastric cancer using LYVE-1 immunohistochemical analysis.","date":"2007","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17145628","citation_count":30,"is_preprint":false},{"pmid":"29262593","id":"PMC_29262593","title":"The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29262593","citation_count":29,"is_preprint":false},{"pmid":"35159221","id":"PMC_35159221","title":"Single-Cell RNA-Seq Reveals a Crosstalk between Hyaluronan Receptor LYVE-1-Expressing Macrophages and Vascular Smooth Muscle Cells.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35159221","citation_count":29,"is_preprint":false},{"pmid":"17265066","id":"PMC_17265066","title":"Basement membrane protein distribution in LYVE-1-immunoreactive lymphatic vessels of normal tissues and ovarian carcinomas.","date":"2007","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/17265066","citation_count":29,"is_preprint":false},{"pmid":"17696907","id":"PMC_17696907","title":"Investigation of intratumoural and peritumoural lymphatics expressed by podoplanin and LYVE-1 in the hybridoma-induced tumours.","date":"2007","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17696907","citation_count":26,"is_preprint":false},{"pmid":"32003471","id":"PMC_32003471","title":"Identification of Lyve-1 positive macrophages as resident cells in meninges of rats.","date":"2020","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32003471","citation_count":25,"is_preprint":false},{"pmid":"29282520","id":"PMC_29282520","title":"TGFβ counteracts LYVE-1-mediated induction of lymphangiogenesis by small hyaluronan oligosaccharides.","date":"2017","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/29282520","citation_count":25,"is_preprint":false},{"pmid":"27733683","id":"PMC_27733683","title":"Homodimerization of the Lymph Vessel Endothelial Receptor LYVE-1 through a Redox-labile Disulfide Is Critical for Hyaluronan Binding in Lymphatic Endothelium.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27733683","citation_count":25,"is_preprint":false},{"pmid":"27356606","id":"PMC_27356606","title":"The selective distribution of LYVE-1-expressing endothelial cells and reticular cells in the reticulo-endothelial system (RES).","date":"2016","source":"Biomedical research (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/27356606","citation_count":24,"is_preprint":false},{"pmid":"16820993","id":"PMC_16820993","title":"Expression and quantification of LYVE-1 in human colorectal cancer.","date":"2006","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16820993","citation_count":23,"is_preprint":false},{"pmid":"23717428","id":"PMC_23717428","title":"The interaction between LYVE-1 with hyaluronan on the cell surface may play a role in the diversity of adhesion to cancer cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23717428","citation_count":22,"is_preprint":false},{"pmid":"23818783","id":"PMC_23818783","title":"Mouse lymphatic endothelial cell targeted probes: anti-LYVE-1 antibody-based magnetic nanoparticles.","date":"2013","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/23818783","citation_count":21,"is_preprint":false},{"pmid":"21782867","id":"PMC_21782867","title":"Induction of LYVE-1/stabilin-2-positive liver sinusoidal endothelial-like cells from embryoid bodies by modulation of adrenomedullin-RAMP2 signaling.","date":"2011","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/21782867","citation_count":20,"is_preprint":false},{"pmid":"22090317","id":"PMC_22090317","title":"Discontinuous LYVE-1 expression in corneal limbal lymphatics: dual function as microvalves and immunological hot spots.","date":"2011","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/22090317","citation_count":20,"is_preprint":false},{"pmid":"20876525","id":"PMC_20876525","title":"Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin alpha2-deficient skeletal muscle.","date":"2011","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/20876525","citation_count":19,"is_preprint":false},{"pmid":"20688736","id":"PMC_20688736","title":"Novel discovery of LYVE-1 expression in the hyaloid vascular system.","date":"2010","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/20688736","citation_count":18,"is_preprint":false},{"pmid":"38532508","id":"PMC_38532508","title":"MRC1 and LYVE1 expressing macrophages in vascular beds of GNAQ p.R183Q driven capillary malformations in Sturge Weber syndrome.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/38532508","citation_count":18,"is_preprint":false},{"pmid":"32034091","id":"PMC_32034091","title":"The cortical actin network regulates avidity-dependent binding of hyaluronan by the lymphatic vessel endothelial receptor LYVE-1.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32034091","citation_count":17,"is_preprint":false},{"pmid":"24573200","id":"PMC_24573200","title":"Three types of macrophagic cells in the mesentery of mice with special reference to LYVE-1-immunoreactive cells.","date":"2014","source":"Biomedical research (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/24573200","citation_count":16,"is_preprint":false},{"pmid":"36496412","id":"PMC_36496412","title":"Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis.","date":"2022","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/36496412","citation_count":16,"is_preprint":false},{"pmid":"29459011","id":"PMC_29459011","title":"The effect of neoadjuvant chemotherapy on the correlation of tumor-associated macrophages with CD31 and LYVE-1.","date":"2017","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29459011","citation_count":15,"is_preprint":false},{"pmid":"16424896","id":"PMC_16424896","title":"Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence.","date":"2006","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/16424896","citation_count":15,"is_preprint":false},{"pmid":"18316062","id":"PMC_18316062","title":"Distribution and organization of lymphatic vessels in the mouse gingiva: An immunohistochemical study with LYVE-1.","date":"2008","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/18316062","citation_count":14,"is_preprint":false},{"pmid":"31250132","id":"PMC_31250132","title":"Elevated lymphatic vessel density measured by Lyve-1 expression in areas of replacement fibrosis in the ventricular septum of patients with hypertrophic obstructive cardiomyopathy (HOCM).","date":"2019","source":"Heart and vessels","url":"https://pubmed.ncbi.nlm.nih.gov/31250132","citation_count":14,"is_preprint":false},{"pmid":"17176958","id":"PMC_17176958","title":"Lymphatic vascular endothelial hyaluronan receptor (LYVE)-1- and CCL21-positive lymphatic compartments in the diabetic thymus.","date":"2006","source":"Anatomical science international","url":"https://pubmed.ncbi.nlm.nih.gov/17176958","citation_count":14,"is_preprint":false},{"pmid":"40875853","id":"PMC_40875853","title":"Septal LYVE1+ macrophages control adipocyte stem cell adipogenic potential.","date":"2025","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/40875853","citation_count":13,"is_preprint":false},{"pmid":"21974896","id":"PMC_21974896","title":"Lymph vessel density in seminomatous testicular cancer assessed with the specific lymphatic endothelium cell markers D2-40 and LYVE-1: correlation with pathologic parameters and clinical outcome.","date":"2011","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21974896","citation_count":12,"is_preprint":false},{"pmid":"39643970","id":"PMC_39643970","title":"IL-17A/CEBPβ/OPN/LYVE-1 axis inhibits anti-tumor immunity by promoting tumor-associated tissue-resident macrophages.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39643970","citation_count":11,"is_preprint":false},{"pmid":"40357547","id":"PMC_40357547","title":"MHCIIhiLYVE1loCCR2hi Interstitial Macrophages Promote Medial Fibrosis in Pulmonary Arterioles and Contribute to Pulmonary Hypertension.","date":"2025","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/40357547","citation_count":11,"is_preprint":false},{"pmid":"33978148","id":"PMC_33978148","title":"Adventitial recruitment of Lyve-1- macrophages drives aortic aneurysm in an angiotensin-2-based murine model.","date":"2021","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/33978148","citation_count":11,"is_preprint":false},{"pmid":"18926287","id":"PMC_18926287","title":"The lymph vessel network in mouse skin visualised with antibodies against the hyaluronan receptor LYVE-1.","date":"2008","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/18926287","citation_count":11,"is_preprint":false},{"pmid":"40113779","id":"PMC_40113779","title":"Structure and unusual binding mechanism of the hyaluronan receptor LYVE-1 mediating leucocyte entry to lymphatics.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40113779","citation_count":11,"is_preprint":false},{"pmid":"38717149","id":"PMC_38717149","title":"LYVE-1-expressing Macrophages Modulate the Hyaluronan-containing Extracellular Matrix in the Mammary Stroma and Contribute to Mammary Tumor Growth.","date":"2024","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38717149","citation_count":10,"is_preprint":false},{"pmid":"23531182","id":"PMC_23531182","title":"Characterization of cells expressing lymphatic marker LYVE-1 in macaque large intestine during simian immunodeficiency virus infection identifies a large population of nonvascular LYVE-1(+)/DC-SIGN(+) cells.","date":"2013","source":"Lymphatic research and biology","url":"https://pubmed.ncbi.nlm.nih.gov/23531182","citation_count":9,"is_preprint":false},{"pmid":"16229916","id":"PMC_16229916","title":"Lymphatic vessel density in vocal cord carcinomas assessed with LYVE-1 receptor expression.","date":"2005","source":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16229916","citation_count":9,"is_preprint":false},{"pmid":"21705651","id":"PMC_21705651","title":"Absence of Nkx2-3 homeodomain transcription factor induces the formation of LYVE-1-positive endothelial cysts without lymphatic commitment in the spleen.","date":"2011","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/21705651","citation_count":8,"is_preprint":false},{"pmid":"27909960","id":"PMC_27909960","title":"Effects of Melatonin, Aluminum Oxide, and Polymethylsiloxane Complex on the Expression of LYVE-1 in the Liver of Mice with Obesity and Type 2 Diabetes Mellitus.","date":"2016","source":"Bulletin of experimental biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27909960","citation_count":8,"is_preprint":false},{"pmid":"21291635","id":"PMC_21291635","title":"LYVE-1 enhances the adhesion of HS-578T cells to COS-7 cells via hyaluronan.","date":"2011","source":"Clinical and investigative medicine. Medecine clinique et experimentale","url":"https://pubmed.ncbi.nlm.nih.gov/21291635","citation_count":8,"is_preprint":false},{"pmid":"37998039","id":"PMC_37998039","title":"Prostaglandin E2 Boosts the Hyaluronan-Mediated Increase in Inflammatory Response to Lipopolysaccharide by Enhancing Lyve1 Expression.","date":"2023","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37998039","citation_count":6,"is_preprint":false},{"pmid":"29633855","id":"PMC_29633855","title":"A novel role of HIF-1α/PROX-1/LYVE-1 axis on tissue regeneration after renal ischaemia/reperfusion in mice.","date":"2018","source":"Archives of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29633855","citation_count":6,"is_preprint":false},{"pmid":"33977630","id":"PMC_33977630","title":"Pilot study supporting the existence of novel lymphatic channels within the canine anterior uveal tract using Lyve-1 and CD31.","date":"2021","source":"Veterinary ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/33977630","citation_count":6,"is_preprint":false},{"pmid":"28026853","id":"PMC_28026853","title":"LYVE1 and PROX1 in the reconstruction of hepatic sinusoids after partial hepatectomy in mice.","date":"2016","source":"Folia morphologica","url":"https://pubmed.ncbi.nlm.nih.gov/28026853","citation_count":6,"is_preprint":false},{"pmid":"32736525","id":"PMC_32736525","title":"FK506 induces lung lymphatic endothelial cell senescence and downregulates LYVE-1 expression, with associated decreased hyaluronan uptake.","date":"2020","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/32736525","citation_count":6,"is_preprint":false},{"pmid":"27877175","id":"PMC_27877175","title":"Thymocytes in Lyve1-CRE/S1pr1f/f Mice Accumulate in the Thymus due to Cell-Intrinsic Loss of Sphingosine-1-Phosphate Receptor Expression.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27877175","citation_count":6,"is_preprint":false},{"pmid":"21500548","id":"PMC_21500548","title":"[Expression of LYVE-1 and Prox-1 in non-small cell lung cancer and the relationship with lymph node metastasis].","date":"2011","source":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","url":"https://pubmed.ncbi.nlm.nih.gov/21500548","citation_count":6,"is_preprint":false},{"pmid":"36736225","id":"PMC_36736225","title":"Single-cell RNA-Seq reveals CVI-mAb-induced Lyve1+ M2-like macrophages reduce atherosclerotic plaque area in Apoe-/- mice.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36736225","citation_count":5,"is_preprint":false},{"pmid":"38566911","id":"PMC_38566911","title":"Novel erectile analyses revealed augmentable penile Lyve-1, the lymphatic marker, expression.","date":"2024","source":"Reproductive medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/38566911","citation_count":5,"is_preprint":false},{"pmid":"36552550","id":"PMC_36552550","title":"Thiocyanate Reduces Motor Impairment in the hMPO-A53T PD Mouse Model While Reducing MPO-Oxidation of Alpha Synuclein in Enlarged LYVE1/AQP4 Positive Periventricular Glymphatic Vessels.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36552550","citation_count":5,"is_preprint":false},{"pmid":"40849271","id":"PMC_40849271","title":"Spatial mapping of rheumatoid arthritis synovial niches reveals a LYVE1+ macrophage network associated with response to therapy.","date":"2025","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40849271","citation_count":5,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52993,"output_tokens":6106,"usd":0.125284},"stage2":{"model":"claude-opus-4-6","input_tokens":9728,"output_tokens":4615,"usd":0.246023},"total_usd":0.371307,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"LYVE-1 is a type I integral membrane glycoprotein with a single extracellular Link module that binds both soluble and immobilized hyaluronan (HA), functioning as the first characterized lymph-specific HA receptor on the luminal face of lymph vessel walls; it is 41% similar to CD44 but absent from blood vessels.\",\n      \"method\": \"Molecular cloning, recombinant protein HA-binding assays, immunolocalization (immunofluorescence and immunoelectron microscopy)\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original identification with multiple orthogonal methods (cloning, binding assay, localization), foundational paper with >1300 citations\",\n      \"pmids\": [\"10037799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Mouse LYVE-1 acts as an endocytic receptor for hyaluronan: it both binds and internalizes HA in transfected 293T fibroblasts in vitro, and is distributed equally on luminal and abluminal surfaces of lymphatic vessels in vivo.\",\n      \"method\": \"Transfection of 293T fibroblasts with murine LYVE-1 cDNA, HA internalization assay, immunoelectron microscopy of lymphatic vessels, LYVE-1/CD44 double-knockout analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of endocytosis combined with in vivo immunoelectron microscopy and genetic control\",\n      \"pmids\": [\"11278811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LYVE-1 surface expression is rapidly and reversibly lost from lymphatic endothelial cells after exposure to TNFα and TNFβ via internalization and lysosomal degradation, coupled with transcriptional shutdown; this internalization is largely HA-independent and occurs in vivo during allergen-induced skin inflammation.\",\n      \"method\": \"Primary lymphatic endothelial cell culture, cytokine treatment, flow cytometry, lysosomal inhibitor studies, ex vivo dermal explants, in vivo murine allergen model, adhesion-blocking mAb 3A\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in vitro and in vivo, rigorous controls, single lab\",\n      \"pmids\": [\"17884820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"LYVE-1 HA-binding activity is functionally silenced in lymphatic endothelial cells by cell-specific autoinhibitory terminal sialylation (via α2-3 or α2-6 linkage to O-glycans); neuraminidase treatment of the native ectodomain reactivates HA binding.\",\n      \"method\": \"Transfection into HEK 293T, Jurkat, CHO, and HeLa cells; mutagenesis of glycosylation sites; glycosylation-defective CHO cell lines; neuraminidase treatment; HA-binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis in multiple cell lines plus enzymatic reactivation, single rigorous study\",\n      \"pmids\": [\"19033446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The LYVE-1 HA-binding domain uses six key residues (Tyr-87, Ile-97, Arg-99, Asn-103, Lys-105, Lys-108) forming a compact, predominantly electrostatic binding surface; unlike CD44, the extended Link module of LYVE-1 requires artificial dimerization for efficient HA binding, and a third conserved disulfide is critical for binding.\",\n      \"method\": \"Truncation mutagenesis, site-directed mutagenesis, recombinant soluble ectodomain production, HA-binding assays, bioluminescent resonance energy transfer (BRET) for dimerization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-function mutagenesis with quantitative binding measurements, multiple orthogonal approaches\",\n      \"pmids\": [\"19887450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LYVE-1 (identical to CRSBP-1) interacts with PDGF-BB and VEGF-A via their CRS motifs; CRSBP-1 ligands induce disruption of VE-cadherin-mediated intercellular adhesion in lymphatic endothelial cells through tyrosine phosphorylation of the CRSBP-1–PDGFβR–β-catenin complex, dissociation of β-catenin and p120-catenin from VE-cadherin, VE-cadherin internalization, and opening of intercellular junctions both in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence microscopy, Transwell permeability assay, PDGFβR kinase inhibitor treatment, FITC-dextran injection in wild-type and Crsbp1-null mice\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, in vitro signaling assays, and in vivo validation with knockout mouse\",\n      \"pmids\": [\"21444752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FGF2 directly binds LYVE-1 with higher affinity than HA or PDGF-BB; glycosylation of LYVE-1 is required for FGF2 binding; soluble LYVE-1 and LYVE-1 knockdown impair FGF2 signaling and FGF2-induced lymphangiogenesis in vivo.\",\n      \"method\": \"AlphaScreen binding assay, surface-immobilization binding, solution-phase binding, CHO cell overexpression, siRNA knockdown in lymphatic endothelial cells, in vivo corneal lymphangiogenesis assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple direct binding assays, functional knockdown, and in vivo confirmation\",\n      \"pmids\": [\"23264596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HA binding by native LYVE-1 in lymphatic endothelium is critically dependent on avidity: receptor self-association above a critical density threshold and/or HA multimerization (via streptavidin or TSG-6 complexes) is required; surface clustering with divalent LYVE-1 mAbs activates binding; endogenous macrophage-surface HA engages LYVE-1 to facilitate macrophage adhesion and transit across lymphatic endothelium.\",\n      \"method\": \"Primary lymphatic endothelial cell HA-binding assays, divalent antibody cross-linking, biotinylated HA multimerization with streptavidin or TSG-6, macrophage adhesion assays on lymphatic endothelium\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal approaches in primary cells establishing avidity mechanism, single rigorous lab study\",\n      \"pmids\": [\"26823460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LYVE-1 forms obligate disulfide-linked homodimers via an unpaired cysteine (Cys-201) in the membrane-proximal domain; homodimerization yields ~15-fold higher HA-binding affinity and ~67-fold slower off-rate than monomers; non-dimerizing mutants fail to bind HA even at high density or after antibody cross-linking; small-angle X-ray scattering (SAXS) indicates the homodimer adopts an 'open scissors' conformation; the Cys-201 disulfide is redox-labile, acting as a potential redox switch.\",\n      \"method\": \"Site-directed mutagenesis of Cys-201, disulfide-linked dimer detection by non-reducing SDS-PAGE, SAXS structural analysis, HA-binding affinity and kinetics measurements, TCEP-HCl reduction assay, lymphatic endothelial cell transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis + SAXS structural data + quantitative binding kinetics in a single rigorous study\",\n      \"pmids\": [\"27733683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LYVE-1 ectodomain shedding is induced by VEGF-A via ERK and ADAM17 in lymphatic endothelial cells; wild-type but not uncleavable LYVE-1 promotes LEC migration in response to VEGF-A, implicating shedding in pathological lymphangiogenesis.\",\n      \"method\": \"Identification of cleavage site, generation of uncleavable LYVE-1 mutant, MEK inhibitor and ADAM17 inhibitor treatment, LEC migration assay, immunostaining in human psoriasis skin and VEGF-A transgenic mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — cleavage site mapping, uncleavable mutant functional rescue, in vitro and in vivo validation\",\n      \"pmids\": [\"26966180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Dendritic cells dock to the basolateral surface of lymphatic vessels and transit to the lumen through HA-mediated interactions with LYVE-1, forming transmigratory cup-like structures; targeted deletion of Lyve1, antibody blockade, or depletion of the DC HA coat delayed lymphatic DC trafficking and blunted CD8+ T cell priming in skin-draining lymph nodes.\",\n      \"method\": \"Intravital microscopy, Lyve1 gene-targeted deletion, anti-LYVE-1 antibody blockade, hyaluronidase treatment of DC HA coat, DC adoptive transfer, in vivo T cell priming assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO, antibody blockade, and enzymatic depletion with defined cellular and immune phenotype, replicated across multiple approaches\",\n      \"pmids\": [\"28504698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Arterial wall LYVE-1+ resident macrophages prevent arterial stiffness and collagen deposition by modulating collagen expression in smooth muscle cells via MMP-9-dependent proteolysis through engagement of LYVE-1 with the HA pericellular matrix of SMCs.\",\n      \"method\": \"Phenotyping and transcriptional profiling of aortic macrophages, targeted deletion of Csf1r, MMP-9 activity assays, co-culture of macrophages and SMCs, collagen quantification, arterial stiffness measurements\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion, transcriptional profiling, enzymatic assay, and functional co-culture in a single study; >267 citations\",\n      \"pmids\": [\"30054204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LYVE-1 lateral diffusion and HA-binding activity in primary lymphatic endothelial cells are regulated by the submembranous cortical actin network: actin disruption increases LYVE-1 diffusion and HA binding; LYVE-1 is transiently entrapped within actin corrals but unlike CD44 does not directly bind actin via cytoplasmic tail motifs.\",\n      \"method\": \"Super-resolution STED microscopy, fluorescence correlation spectroscopy, single-particle tracking, co-immunoprecipitation with actin, actin-disrupting drug treatments, HA-binding assays in primary LECs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple biophysical methods (STED, FCS, SPT) plus biochemical co-IP and functional binding assays in primary cells\",\n      \"pmids\": [\"32034091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LMW-HA stimulation of lymphatic endothelial cells through LYVE-1 induces actin cytoskeleton rearrangement and rapid tyrosine phosphorylation of PKCα/βII and ERK1/2; neutralizing anti-LYVE-1 antibodies block these effects as well as LEC proliferation, migration, and tube formation.\",\n      \"method\": \"Primary LEC culture, anti-LYVE-1 neutralizing antibody, western blotting for phospho-PKC and phospho-ERK, actin immunofluorescence, proliferation and migration assays, tube formation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional antibody blockade with signaling readouts, single lab, moderate evidence\",\n      \"pmids\": [\"24667755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LMW-HA increases colocalization of LYVE-1 and S1P receptor S1P3 at the LEC surface; silencing either LYVE-1 or S1P3 inhibits LMW-HA-induced tube formation and blocks Src and ERK1/2 phosphorylation, indicating cooperative signaling between LYVE-1 and S1P3 in LMW-HA-mediated lymphangiogenesis.\",\n      \"method\": \"Immunofluorescence colocalization, co-immunoprecipitation, siRNA knockdown of LYVE-1 or S1P3, phospho-Src and phospho-ERK western blot, tube formation assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — co-IP and siRNA with functional readouts, single lab\",\n      \"pmids\": [\"26116468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LYVE-1 knockout mice display normal lymphatic vessel ultrastructure and function, normal hyaluronan levels in tissue and blood, normal dendritic cell trafficking, normal skin inflammation resolution, and normal tumor growth, indicating LYVE-1 is not obligatory for these processes under normal conditions.\",\n      \"method\": \"Targeted gene replacement with beta-galactosidase reporter, immunoelectron microscopy, HA quantification in blood and tissue, DC trafficking assays, oxazolone inflammation model, tumor transplant models\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive KO phenotyping with multiple functional assays; foundational loss-of-function study\",\n      \"pmids\": [\"17101772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LYVE-1/CD44 double-knockout mice show increased edema formation in a carrageenan-induced paw inflammation model compared to wild-type, but not to single knockouts, suggesting LYVE-1 and CD44 have overlapping roles in inflammation, though neither is individually required for lymphatic formation or function.\",\n      \"method\": \"Generation of LYVE-1/CD44 double KO mice, histology, intravital microscopy, carrageenan-induced edema model\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with double KO and functional edema readout, single lab\",\n      \"pmids\": [\"19170073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FK506 (tacrolimus) downregulates LYVE-1 mRNA and protein in lymphatic endothelial cells through an NFAT-dependent transcriptional mechanism (identified via luciferase reporter assay with NFAT binding site on LYVE-1 promoter), resulting in decreased HA uptake; this effect was confirmed ex vivo in precision-cut lung slices.\",\n      \"method\": \"LEC culture, luciferase reporter assay with NFAT binding site mutagenesis, western blot, flow cytometry, HA uptake assay, ex vivo lung slice treatment\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter with mutagenesis plus functional HA uptake assay, single lab\",\n      \"pmids\": [\"32736525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Small HA (sHA) oligosaccharides promote LEC proliferation and lymphangiogenesis in a LYVE-1-dependent manner (using sialylated LYVE-1, not CD44 or TLR-4); higher sHA concentrations induce TGFβ in LECs to counter-regulate this proliferation; effects confirmed with LYVE-1 knockout mice and blocking antibodies.\",\n      \"method\": \"Primary LEC proliferation assays, ex vivo lymphangiogenesis assay, in vivo intradermal injection, LYVE-1 KO mice, blocking antibodies, TGFβ measurement\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and antibody blockade with multiple functional assays, single lab\",\n      \"pmids\": [\"29282520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"OPN (osteopontin) acts as a ligand for LYVE-1 on tissue-resident macrophages (TRM-TAMs); OPN/LYVE-1 signaling activates the JNK/c-Jun pathway, promoting proliferation of immunosuppressive LYVE-1+ TRM-TAMs; IL-17A stimulates tumor cell CEBPβ to produce OPN; LYVE-1 deletion in macrophages inhibited TRM-TAM expansion and enhanced anti-tumor responses.\",\n      \"method\": \"In vitro signaling assays (JNK/c-Jun phosphorylation), macrophage-specific LYVE-1 conditional KO, OPN neutralization, IL-17A neutralization, tumor growth models, flow cytometry\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway placement, conditional KO with defined immune phenotype, single lab\",\n      \"pmids\": [\"39643970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Crystal structures of murine and human LYVE-1 bound to hyaluronan reveal a highly unusual 'sliding' mode of ligand interaction (unlike the conventional 'sticking' mode of CD44): LYVE-1 grabs free HA chain-ends and winds them through conformational rearrangements in a deep binding cleft lubricated by structured waters, providing a low-tack adhesive interaction that allows migrating immune cells to slide through endothelial junctions while retaining their HA glycocalyx.\",\n      \"method\": \"X-ray crystallography of murine and human LYVE-1–HA complexes, surface plasmon resonance/binding mechanics, functional validation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures of two species with mechanistic functional validation, rigorous single study\",\n      \"pmids\": [\"40113779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Septal adipose tissue macrophages (sATMs) marked by LYVE-1 and CD209b reside in close proximity to adipocyte stem cells (ASCs) in the WAT septum; sATMs instruct ASC differentiation into white adipocytes through TGFβ1; depletion of sATMs or myeloid-specific loss of TGFβ1 redirects ASC fate toward thermogenic (beige) adipocytes and protects against diet-induced obesity.\",\n      \"method\": \"Genetic mouse model of LYVE-1+ macrophage depletion, TGFβ1 conditional KO in tissue-resident macrophages, adipocyte lineage tracing, co-culture of sATMs and ASCs, metabolic phenotyping\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic depletion with conditional cytokine KO and co-culture functional rescue, rigorous mechanistic dissection\",\n      \"pmids\": [\"40875853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LYVE-1 expressed on primary effusion lymphoma (PEL) cells interacts and colocalizes with emmprin (CD147) and BCRP/ABCG2 at the cell surface; RNA interference targeting of LYVE-1 enhances chemotherapy-induced apoptosis, and disruption of HA-receptor interactions with small HA oligosaccharides reduces emmprin and BCRP expression, sensitizing PEL cells to chemotherapy.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence colocalization, siRNA knockdown of LYVE-1, apoptosis assay, small HA oligosaccharide treatment\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — reciprocal co-IP with siRNA functional validation, single lab\",\n      \"pmids\": [\"21660043\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LYVE-1 is a type I transmembrane Link superfamily glycoprotein that forms obligate redox-labile disulfide homodimers (via Cys-201) and binds hyaluronan through a sliding, avidity-dependent mechanism requiring receptor clustering above a critical density threshold, a process constrained by the cortical actin network; in lymphatic endothelium it is functionally silenced by terminal sialylation of O-glycans and can be activated by cytokine-induced internalization or ligand multimerization, enabling it to serve as a docking receptor for dendritic cell and macrophage HA glycocalyx to mediate lymphatic entry and immune trafficking, to interact with FGF2 and growth factor co-receptors to regulate lymphangiogenesis, to activate intracellular signaling (PKC, ERK, JNK) downstream of low-MW HA, and to mediate MMP-9-dependent regulation of smooth muscle cell collagen by perivascular macrophages; its transcription is regulated by NFAT, and its ectodomain can be shed by ADAM17 downstream of VEGF-A/ERK signaling to promote LEC migration.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LYVE-1 is a lymphatic endothelial hyaluronan receptor of the Link superfamily that serves as a docking platform for immune cell trafficking across lymphatic vessels and as a co-receptor for growth factor signaling during lymphangiogenesis. It forms obligate disulfide-linked homodimers via Cys-201, adopting an open-scissors conformation that binds hyaluronan through a unique sliding mechanism—grabbing free HA chain-ends into a deep cleft—with ~15-fold higher affinity than monomers, and its HA-binding activity is regulated by avidity-dependent receptor clustering, autoinhibitory sialylation of O-glycans, cortical actin corralling, and redox-sensitive disulfide switching [PMID:27733683, PMID:40113779, PMID:19033446, PMID:26823460, PMID:32034091]. Dendritic cells and macrophages dock to LYVE-1 via their HA glycocalyx to transit lymphatic endothelium, forming transmigratory cups that facilitate immune cell entry and CD8+ T cell priming; on perivascular macrophages, LYVE-1 engagement with smooth muscle cell HA drives MMP-9-dependent collagen regulation to maintain arterial compliance [PMID:28504698, PMID:30054204]. LYVE-1 also directly binds FGF2, PDGF-BB, VEGF-A, and osteopontin, coupling to intracellular signaling cascades including PKC/ERK, Src, and JNK/c-Jun, while its ectodomain is shed by ADAM17 downstream of VEGF-A/ERK to promote lymphatic endothelial cell migration [PMID:23264596, PMID:21444752, PMID:39643970, PMID:26966180].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"The identification of LYVE-1 as a lymph vessel-specific HA receptor established the first molecular distinction between lymphatic and blood vascular endothelium and opened the question of how HA transport and signaling occur in lymphatics.\",\n      \"evidence\": \"Molecular cloning, recombinant HA-binding assays, and immunolocalization by immunofluorescence and immunoelectron microscopy\",\n      \"pmids\": [\"10037799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural information on the HA-binding mode\", \"Functional role in vivo unknown\", \"Signaling capacity not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstration that LYVE-1 acts as an endocytic receptor for HA, distributed on both luminal and abluminal lymphatic surfaces, established it as an active HA uptake mediator rather than merely a passive adhesion molecule.\",\n      \"evidence\": \"Transfection of 293T cells with murine LYVE-1, HA internalization assays, immunoelectron microscopy of lymphatic vessels\",\n      \"pmids\": [\"11278811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endocytic pathway and sorting signals not defined\", \"Physiological relevance of HA uptake not tested in vivo\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"A comprehensive LYVE-1 knockout revealed unexpectedly normal lymphatic morphology, HA homeostasis, and DC trafficking under baseline conditions, raising the question of functional redundancy versus context-dependent activation.\",\n      \"evidence\": \"Targeted gene replacement in mice with multiple functional assays including HA quantification, DC trafficking, and tumor models\",\n      \"pmids\": [\"17101772\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compensatory mechanisms (e.g., CD44) not fully dissected\", \"Inflammatory or stress-dependent phenotypes not comprehensively explored\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The finding that TNFα/β drive rapid internalization and degradation of LYVE-1 in inflamed lymphatics showed that receptor surface availability is dynamically regulated by inflammatory cytokines, explaining context-dependent function.\",\n      \"evidence\": \"Primary LEC culture with cytokine treatment, flow cytometry, lysosomal inhibitors, in vivo murine allergen model\",\n      \"pmids\": [\"17884820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trafficking route and sorting signals for internalization undefined\", \"Whether internalization serves a signaling versus clearance function unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that autoinhibitory sialylation of O-glycans silences LYVE-1 HA binding on LECs, reversible by neuraminidase, revealed a glycan-based gating mechanism that explains why the receptor is not constitutively active despite high surface expression.\",\n      \"evidence\": \"Transfection into multiple cell lines, glycosylation site mutagenesis, glycosylation-defective cell lines, neuraminidase treatment and HA-binding assays\",\n      \"pmids\": [\"19033446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the sialyltransferase(s) responsible not determined\", \"Physiological signals that trigger desialylation in vivo unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapping the HA-binding surface to six key residues and showing that dimerization is required for efficient binding established the structural basis for LYVE-1's low intrinsic affinity and its dependence on avidity, distinguishing it mechanistically from CD44.\",\n      \"evidence\": \"Site-directed and truncation mutagenesis, recombinant ectodomain binding assays, BRET dimerization measurements\",\n      \"pmids\": [\"19887450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution structure yet available\", \"How dimerization is regulated in vivo unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"LYVE-1/CD44 double-knockout mice showed enhanced inflammatory edema compared to single knockouts, providing genetic evidence for overlapping HA receptor functions in inflammation and partially explaining the mild single-KO phenotype.\",\n      \"evidence\": \"Double-KO mice, carrageenan-induced paw edema model, intravital microscopy\",\n      \"pmids\": [\"19170073\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Other compensating HA receptors not excluded\", \"Mechanism of edema regulation not molecularly defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of LYVE-1 (as CRSBP-1) as a co-receptor for PDGF-BB and VEGF-A that disrupts VE-cadherin junctions via PDGFβR/β-catenin phosphorylation expanded the receptor's role from HA binding to growth factor signaling and junctional permeability regulation.\",\n      \"evidence\": \"Co-immunoprecipitation, Transwell permeability assay, kinase inhibitors, FITC-dextran injection in WT and Crsbp1-null mice\",\n      \"pmids\": [\"21444752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and direct binding interface between LYVE-1 and PDGFβR not resolved\", \"Whether this pathway operates in all lymphatic beds unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstration of direct FGF2 binding to LYVE-1 with higher affinity than HA, and its requirement for FGF2-induced lymphangiogenesis, established LYVE-1 as a multi-ligand co-receptor for angiogenic growth factors beyond the HA axis.\",\n      \"evidence\": \"AlphaScreen and surface-immobilization binding assays, siRNA knockdown, in vivo corneal lymphangiogenesis\",\n      \"pmids\": [\"23264596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"FGF2 binding site on LYVE-1 not structurally mapped\", \"Relationship between FGF2 and HA binding (competitive or cooperative) not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"LMW-HA-induced activation of PKCα/βII and ERK1/2 signaling through LYVE-1 in LECs, blocked by neutralizing antibodies, placed LYVE-1 upstream of intracellular kinase cascades that drive lymphangiogenic cell behaviors.\",\n      \"evidence\": \"Primary LEC culture, anti-LYVE-1 antibody blockade, western blotting for phospho-PKC and phospho-ERK, tube formation and migration assays\",\n      \"pmids\": [\"24667755\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct signaling adapter linking LYVE-1 cytoplasmic tail to PKC/ERK not identified\", \"Single-lab finding without independent replication\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Cooperative signaling between LYVE-1 and S1P3 in LMW-HA-mediated lymphangiogenesis, via Src and ERK1/2, revealed LYVE-1 participates in receptor crosstalk beyond its own cytoplasmic signaling capacity.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown of LYVE-1 or S1P3, phospho-Src and phospho-ERK western blot, tube formation assay\",\n      \"pmids\": [\"26116468\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether LYVE-1–S1P3 interaction is direct or scaffold-mediated not determined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Three concurrent studies resolved the biophysical mechanism of LYVE-1 HA binding: obligate Cys-201 disulfide homodimerization provides a redox-labile switch controlling affinity; avidity-dependent clustering above a threshold density is required for binding on native LECs; and VEGF-A/ERK-driven ADAM17 shedding of the ectodomain promotes LEC migration.\",\n      \"evidence\": \"Mutagenesis of Cys-201 with SAXS structural analysis and binding kinetics; divalent antibody cross-linking and HA multimerization assays; cleavage site mapping with uncleavable mutant and ADAM17 inhibitor studies\",\n      \"pmids\": [\"27733683\", \"26823460\", \"26966180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological redox signals controlling the Cys-201 switch unidentified\", \"Signals that cluster LYVE-1 above the threshold in vivo unknown\", \"Fate and function of shed ectodomain in vivo not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"In vivo demonstration that DCs dock to LYVE-1 via their HA glycocalyx and form transmigratory cups for lymphatic entry, with LYVE-1 deletion delaying DC trafficking and blunting CD8+ T cell priming, established the first non-redundant immune function for LYVE-1 that the earlier KO had missed.\",\n      \"evidence\": \"Intravital microscopy, Lyve1 gene-targeted deletion, antibody blockade, hyaluronidase treatment of DC HA coat, adoptive DC transfer, T cell priming assays\",\n      \"pmids\": [\"28504698\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether all DC subsets use this pathway equally unclear\", \"Structural basis of transmigratory cup formation not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"LYVE-1+ perivascular macrophages were shown to prevent arterial stiffness by engaging smooth muscle cell HA and inducing MMP-9-dependent collagen regulation, extending LYVE-1 function from lymphatic biology to vascular homeostasis.\",\n      \"evidence\": \"Aortic macrophage profiling, Csf1r deletion, MMP-9 activity assays, macrophage–SMC co-culture, arterial stiffness measurements\",\n      \"pmids\": [\"30054204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LYVE-1 engagement directly triggers MMP-9 secretion or acts indirectly not resolved\", \"Relevance to human arterial disease not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Super-resolution imaging revealed that cortical actin corrals regulate LYVE-1 lateral diffusion and clustering, constraining HA-binding capacity independently of direct cytoplasmic tail–actin interactions, adding a cytoskeletal layer to the avidity-gating model.\",\n      \"evidence\": \"STED microscopy, fluorescence correlation spectroscopy, single-particle tracking, co-IP with actin, actin-disrupting drugs in primary LECs\",\n      \"pmids\": [\"32034091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of linker proteins mediating indirect actin coupling unknown\", \"How cytokine signals remodel actin corrals to activate LYVE-1 not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"NFAT-dependent transcription of LYVE-1 was demonstrated, with FK506 suppressing LYVE-1 expression and HA uptake, linking calcineurin/NFAT signaling to lymphatic HA clearance.\",\n      \"evidence\": \"Luciferase reporter with NFAT-site mutagenesis, western blot, flow cytometry, HA uptake assay, ex vivo lung slices\",\n      \"pmids\": [\"32736525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which NFAT family member is responsible not specified\", \"In vivo significance for transplant-associated lymphatic dysfunction not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Osteopontin was identified as a non-HA ligand for LYVE-1 on tumor-associated macrophages, activating JNK/c-Jun to expand immunosuppressive LYVE-1+ macrophages, linking LYVE-1 to tumor immune evasion beyond its classical HA-binding role.\",\n      \"evidence\": \"In vitro JNK/c-Jun signaling assays, macrophage-specific LYVE-1 conditional KO, OPN neutralization, tumor growth models\",\n      \"pmids\": [\"39643970\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"OPN binding site on LYVE-1 not mapped\", \"Whether OPN competes with HA for LYVE-1 binding unknown\", \"Single-lab finding requiring independent validation\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Crystal structures of LYVE-1–HA complexes from two species revealed a unique 'sliding' binding mode in which LYVE-1 grabs free HA chain-ends and winds them through a deep, water-lubricated cleft, explaining how immune cells retain their HA glycocalyx while sliding through lymphatic junctions—resolving the long-standing puzzle of low-tack adhesion.\",\n      \"evidence\": \"X-ray crystallography of murine and human LYVE-1–HA complexes, surface plasmon resonance, functional validation\",\n      \"pmids\": [\"40113779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the sliding mechanism applies equally to all HA polymer sizes not tested\", \"How sialylation inhibits binding at the structural level not shown in these structures\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"LYVE-1+ septal adipose tissue macrophages were found to instruct white adipocyte differentiation via TGFβ1, with their depletion redirecting adipocyte progenitors toward thermogenic beige fate and protecting against obesity, revealing a metabolic regulatory role for LYVE-1+ macrophages.\",\n      \"evidence\": \"Genetic depletion of LYVE-1+ macrophages, myeloid-specific TGFβ1 conditional KO, adipocyte lineage tracing, metabolic phenotyping\",\n      \"pmids\": [\"40875853\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LYVE-1 itself transduces signals in sATMs or serves only as a marker not distinguished\", \"Relevance to human obesity not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the physiological signals that desialylate or cluster LYVE-1 above its activation threshold in vivo, the identity of cytoplasmic signaling adaptors, whether the sliding binding mode generalizes across all polymer contexts, and whether LYVE-1's roles on tissue-resident macrophages reflect receptor-mediated signaling or merely mark a macrophage subset.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Physiological desialylation trigger unknown\", \"No cytoplasmic adaptor or signaling scaffold identified\", \"Functional distinction between LYVE-1 as receptor vs. macrophage subset marker not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0, 1, 7, 8, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 6, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 7, 8, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0168256\", \"supporting_discovery_ids\": [10, 11, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 13, 14]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FGF2\",\n      \"PDGFB\",\n      \"VEGFA\",\n      \"PDGFRB\",\n      \"S1PR3\",\n      \"SPP1\",\n      \"BSG\",\n      \"ADAM17\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}